Friday, 1 March 2019

STD-AIDS and Infectious Diseases






Book your slot @ 2nd Global experts meet on Std-Aids and Infectious Diseases
Visit: stdmeet.conferenceseries.com
Email: stdaids@worldhealthsummit.net
Posted by at 2 comments:

Wednesday, 27 February 2019

Keynote and Special Session





A protagonist of honest and ethical practice he was decorated with GUARDIAN OF SURAT city award in year 2010. Dr Ashok Kapse is a highly sought-after speaker, he has delivered hundreds of lectures on Dengue, Malaria, Typhoid and antibiotic uses across the India. He has addressed international conferences in Thailand, Malaysia, Finland, Spain, UAE, USA and UK. He has addressed 8-international conferences in last 5-yrears. Dr Ashok Kapse is an avid clinical photographer his pictures figure into various books and atlases including Atlas of tropical diseases published by American academy of Pediatrics. Dr. Ashok Kapse believes that exposure to Sun & Solar rays are the most vital health measure for human being, he also believes that restoring Vitamin D sufficiency has potential to wipe away lots of human diseases. He has been conducting CME on role of Vitamin D in various aspects of human health; till far he has addressed >100 CME at various places including at Rovaniemi Finland, Abu Dhabi, Dubai & Madrid Spain.


Posted by at 2 comments:

Monday, 25 February 2019

A New Treatment for HIV


Late last month, the U.S. Food and Drug Administration approved two new medications to help treat HIV-1, the most common strain of the virus. This announcement marks the latest development in new treatment options available for people who live with HIV.
On August 30, drug manufacturer, Merck, announced that the FDA gave its stamp of approval to two new antiretroviral medications — Delstrigo and Pifeltro. These are oral medications meant for HIV-positive adults who haven’t received antiretroviral treatments previously. These drugs aren’t for those who’ve already been receiving antiretroviral treatment for HIV. The approval came about after successful phase III trials for Delstrigo and Pifeltro that involved over 700 participants for each drug. Interestingly, both medications showed signs of lowered cholesterol as a somewhat surprising side effect.
“Fortunately, the HIV population is aging — they are living longer and longer, and I think statistics show that soon, if not already, the majority of people living with HIV will be over 50. So, more likely, they will have comorbidities like high cholesterol — all these things you get when you get old,” Dr. Carey Hwang, executive director and product development lead, global clinical development – infectious diseases at Merck Research Laboratories, said. “We don’t expect any real significant drug interactions with a lot of the medicines used to treat these comorbidities.”


Posted by at 1 comment:

Tuesday, 5 December 2017

STD-AIDS-2019

About Conference


The exciting and innovative program brought together national and international experts to promote the exchange of the latest clinical practices and cutting-edge research in STD-AIDS and Infectious Diseases. State-of-the-Art Lectures, Free Communication Sessions and Clinical and Scientific Educational Symposia, were appreciated by the 2017 attendees. With this enthusiastic support of our Organizing Committee and Editorial Board Member, we are overwhelmed to announce Global Experts Meet on STD-AIDS and Infectious Diseases as a continuum of our previous successful conference. It will be held on April 08-09,2019 Wellington, New Zealand. The conference will focus on “Advancing Innovative Treatments and Therapeutics in Preventing STD-AIDS and Infectious Diseases”.


The field of STD-AIDS and Infectious diseases is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

ConferenceSeries LLC Ltd is a pioneer and leading scientific event organizer, publishing around 700 Open access journals and conducting over 500 Scientific Meetings all over the globe annually with the support of more than 1000 scientific associations, 80000 editorial board members and 7.5 million followers to its credit.

 Why to attend?

STD-AIDS-2018 highlights the theme “Advancing innovative treatments and therapeutics in preventing STD-AIDS and Infectious diseases” Which focus on the latest advancements in prevention and treatment cure of various STD-AIDS which are occurring from one person to another during sexual contact. 

STD-AIDS-2018 provides two days robust discussions on methods and strategies related to diagnosis, prevention and management of STD-AIDS and Infectious diseases as well as explore new ideas and concepts on a global scale. This two day event provides a perfect platform for leading scientists, researchers, scholars, practitioners, health care experts, treatment providers, equipment and diagnostic tools manufacturers/vendors, to gain knowledge about the latest advancements in clinical research and health diagnostics within the respective field and also encourages new innovations, research ideas around the globe. 

Other Reasons:
  • World Class Speakers and Fresh New Talent from across the Globe in Health Industry
  • Packed Schedule: Workshops, Multi-track Conference, Expo area and more...
  • To educate yourself on the diagnosis and treatment of STD-AIDS and Infectious diseases.
  • To enhance your ability to treat the growing number of patients affected by these diseases.
  • To network with your fellow primary care clinicians.
  • To empower yourself to fill the void created by the national shortage of participants.
Intended Participants:
  • Virologists
  • Bacteriologists
  • Microbiologists
  • STD-AIDS associations and societies
  • Epidemiologists
  • Health care professionals
  • Research scholars
  • Medical colleges
  • Infectious Diseases Researchers
  • Viral Diseases Researchers

Conference Highlights


Special Issues


  •  All accepted abstracts will be published in respective Supporting International Journals.
  •  Abstracts will be provided with Digital Object Identifier by Cross Ref.

Posted by at 7 comments:
Subscribe to: Posts (Atom)